Armata Pharmaceuticals develops pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections. News about ARMP centers on its late clinical-stage phage pipeline, including AP-SA02 for Staphylococcus aureus bacteremia and AP-PA02 for Pseudomonas aeruginosa, FDA designations and regulatory interactions, scientific publications on phage structure, and clinical program updates.
Company updates also cover financial results, research and development spending, grant-supported program activity, credit agreement and warrant amendments with Innoviva-related entities, and board or annual-meeting governance matters. Armata describes in-house phage-specific cGMP manufacturing as part of its development model.
Armata Pharmaceuticals (ARMP) announced two issued U.S. patents protecting treatment methods using its clinical bacteriophage candidates AP-SA02 and AP-PA02.
Patent No. 12,751,983, issued October 6, 2026, covers treatment of Staphylococcus aureus infections using AP-SA02. Armata expects protection until at least February 2041. Patent No. 12,594,312, issued April 7, 2026, covers treatment of Pseudomonas infections using AP-PA02, with expected protection until about January 4, 2043.
The portfolio now includes 101 issued patents and 60 pending applications across 15 patent families, with nominal expiration dates through 2046. Armata plans to begin a Phase 3 superiority study, designed to test whether AP-SA02 provides better treatment results, in complicated S. aureus bloodstream infections in the second half of 2026.
Armata Pharmaceuticals (ARMP) received an additional $3.7 million in non-dilutive funding from the U.S. Department of War to support Phase 3 development of its lead bacteriophage candidate AP-SA02 for complicated Staphylococcus aureus bacteremia (SAB).
The new commitment is the first funding earmarked specifically for Phase 3 execution under a previously awarded Department of War grant administered through MTEC and managed by NMRC–NAMD, with funding from the Defense Health Agency and Joint Warfighter Medical Research Program. This raises total non-dilutive backing for AP-SA02 to approximately $32.4 million.
AP-SA02, a fixed multi-phage cocktail given adjunctively to antibiotics for SAB caused by MSSA or MRSA, holds QIDP, Fast Track, and Breakthrough Therapy designations from the FDA. Positive Phase 2a diSArm data were previously presented, and Armata plans to initiate a Phase 3 superiority study in the second half of 2026.
Armata Pharmaceuticals (ARMP) has received U.S. FDA Breakthrough Therapy designation for AP-SA02 for adjunct treatment of complicated Staphylococcus aureus bacteremia caused by MSSA or MRSA.
The designation is based on Phase 1b/2a diSArm study data in adults, where intravenous AP-SA02 added to best available antibiotic therapy showed higher and earlier clinical cure rates than placebo plus antibiotics, with no serious adverse events attributed to AP-SA02. At 28-day end-of-study, 100% of AP-SA02 patients maintained clinical response without relapse versus 75% on placebo. AP-SA02 now holds Breakthrough, Fast Track and QIDP designations, giving access to expedited FDA development and review pathways. Phase 3 superiority testing in complicated SAB is planned to start in the second half of 2026 and is partially supported by a $28.7 million Department of War award.
Armata Pharmaceuticals (ARMP) will deliver a corporate presentation at the H.C. Wainwright 28th Annual Global Investment Conference in New York on September 16, 2026.
Chief Executive Officer Deborah Birx, M.D., is scheduled to present from 11:00 am to 11:30 am EDT on Wednesday, September 16, 2026. The company develops high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections and is advancing clinical phage candidates targeting Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens.
Armata Pharmaceuticals (ARMP) announced publication of a peer-reviewed paper in the Journal of Molecular Biology that provides an integrative structural atlas of Ar-KM, a therapeutic phiKMV-like bacteriophage targeting Pseudomonas aeruginosa, the pathogen addressed by Armata’s inhaled phage candidate AP-PA02.
The study uses cryo-electron microscopy, proteomics and bioinformatics to capture three distinct structural states of Ar-KM from a single purified preparation and to build atomic models for eleven structural proteins at near-atomic resolution. The work explains how Ar-KM keeps its genome securely packaged before infection, identifies an enzyme activity that helps the phage penetrate the bacterial cell envelope, and characterizes a previously unrecognized protein involved in coordinated genome release and delivery. Armata highlights that these insights link fundamental phage biology to properties important for therapeutic development, such as stability, infectivity and efficient genome delivery, and are supported by its proprietary phage purification processes.
Armata Pharmaceuticals (NYSE American: ARMP) reported second quarter 2026 results and detailed progress on its lead phage therapeutic AP-SA02 for complicated Staphylococcus aureus bacteremia. The company submitted a finalized Phase 3 superiority trial protocol to the FDA, completed key manufacturing assays and engineering runs, and obtained FDA Fast Track designation plus an Agreed Initial Pediatric Study Plan. Armata received an additional $2.5 million in non-dilutive funding from the U.S. Department of War, bringing that award’s total to $28.7 million. For Q2 2026, grant and award revenue was $2.5 million, operating loss was $10.3 million, and net income was $74.1 million driven by a $91.0 million non-cash gain on its Convertible Loan. Cash and cash equivalents rose to $24.0 million at June 30, 2026, following a $25.0 million term loan and at-the-market equity issuance.
Armata Pharmaceuticals (NYSE American: ARMP) reported multiple milestones supporting the planned Phase 3 superiority study of AP-SA02, its intravenous multi-phage candidate for adjunct treatment of complicated Staphylococcus aureus bacteremia caused by MSSA or MRSA. The company submitted the complete Phase 3 protocol and comprehensive responses to all U.S. FDA comments from the End-of-Phase 2 meeting, covering clinical, Chemistry, Manufacturing and Controls, and regulatory topics. Armata also completed four engineering runs of AP-SA02 at its in-house cGMP facility in Los Angeles, with production of Phase 3 clinical trial material as the next step. In June 2026, Armata received an additional $2.5 million continuation award from the U.S. Department of Defense, bringing total funding under this award to $28.7 million to support Phase 3 preparations. The pivotal trial remains on track to initiate in the second half of 2026 and is intended to support a future BLA. The company promoted David House to Chief Financial Officer to support late-stage development and strategy execution.
Armata Pharmaceuticals (NYSE American: ARMP) reported that the U.S. FDA has agreed to an Initial Pediatric Study Plan (Agreed iPSP) for AP-SA02 as adjunct treatment of complicated Staphylococcus aureus bacteremia (SAB) in pediatric patients, fulfilling a key regulatory requirement before a future Biologics License Application (BLA).
The Agreed iPSP defines a pediatric program for patients up to 17 years, aligned with the adult SAB indication. According to Armata, FDA, under the Pediatric Research Equity Act and aligned with EMA frameworks, agreed that pediatric studies will be deferred until adult safety and efficacy data are generated in a planned Phase 3 program, expected to initiate in the second half of 2026.
Following completion of the adult Phase 3 study, Armata plans a single multicenter, open-label pediatric trial to evaluate safety, tolerability and clinical response, creating a structured pathway to potentially expand AP-SA02 use into pediatric populations while prioritizing patient safety.
Armata Pharmaceuticals (NYSE American: ARMP) received an additional $2.5 million in non-dilutive funding from the U.S. Department of Defense for lead candidate AP-SA02, raising the award total to $28.7 million.
The funds support Phase 3 readiness of intravenous AP-SA02 for adjunct treatment of complicated Staphylococcus aureus bacteremia caused by MSSA or MRSA, with plans to initiate a Phase 3 superiority study in the second half of 2026.
Armata Pharmaceuticals (NYSE American: ARMP) reported first quarter 2026 results and a corporate update. Grant revenue rose to $0.8 million, R&D expenses to $6.1 million, G&A to $3.5 million, and loss from operations to $8.8 million. Net loss was $115.3 million versus $6.5 million a year earlier.
The company is preparing a Phase 3 AP-SA02 study in complicated S. aureus bacteremia, targeting initiation in the second half of 2026. AP-SA02 received FDA Fast Track and QIDP designations. Armata entered a new $25 million secured credit agreement with Innoviva maturing in 2029 and extended prior Innoviva credit maturities to 2027. Cash and equivalents were $4.8 million at March 31, 2026.